Setmelanotide (Imcivree) is a precision obesity drug for rare genetic obesity — specific deficiencies in the leptin–melanocortin pathway (POMC/PCSK1, LEPR) and Bardet-Biedl syndrome. It directly activates the MC4R appetite receptor downstream of the defect. It is only for patients with a confirmed qualifying diagnosis — not a general weight-loss medication.
Obesity Medication Library entry. Section accent: family --teal.
DRUG FACT PANEL
| Generic | Setmelanotide |
| Brand | Imcivree |
| Class | Melanocortin-4 receptor (MC4R) agonist |
| Mechanism (1 line) | Directly activates the MC4R appetite pathway that is impaired in specific genetic deficiencies upstream |
| FDA indication | Chronic weight management in patients with obesity due to specific genetic deficiencies — POMC, PCSK1 or LEPR deficiency, and Bardet-Biedl syndrome (in eligible ages per label) |
| Who it's for | Only patients with a confirmed qualifying genetic diagnosis — not a general obesity drug |
| Route/formulation | Subcutaneous injection, once daily |
| Titration concept | Started low and adjusted; used only after genetic confirmation — individual dosing is set by a specialist, not this page |
| Expected effect | Meaningful weight and hunger reduction in the qualifying genetic populations [verify]; not applicable to common obesity |
| Evidence level | Grade A 🟢 for the labelled genetic conditions; not indicated (no benefit expected) for common polygenic obesity |
What setmelanotide is
Setmelanotide is unlike every other drug in this library: it is not a general obesity treatment but a precision therapy for defined rare genetic forms of obesity. These are monogenic disorders of the leptin–melanocortin pathway, the brain circuit that translates the body's energy signals into appetite. When a single gene in that pathway is broken, the result is early-onset, severe obesity with intense, unrelenting hunger (hyperphagia). Setmelanotide replaces the missing signal at the point of the MC4R receptor. → Genetics of Obesity
How it works — and why the pathway matters
The pathway runs roughly: leptin → LEPR receptor → POMC neuron → (POMC processed by PCSK1) → melanocortin peptides → MC4R receptor → reduced appetite. A loss-of-function mutation anywhere upstream (LEPR, POMC, PCSK1) starves the MC4R receptor of its signal, so appetite is never adequately suppressed. Bardet-Biedl syndrome disrupts the same signalling through a different (ciliary) mechanism.
Setmelanotide is an MC4R agonist — it activates the receptor directly, bypassing the broken upstream step. That is why it works specifically in these conditions and would not be expected to help common obesity, where the pathway is intact. It is a textbook example of matching the mechanism to the biology. → The Next Generation of Obesity Medicine
What the trials actually show
In the pivotal studies, patients with confirmed POMC/PCSK1 or LEPR deficiency, and separately Bardet-Biedl syndrome, achieved meaningful weight reduction and marked reductions in hunger — often the most disabling symptom. Because these are rare diseases, trials were small and single-arm by necessity; the effect within the qualifying population is nonetheless clear and clinically important [verify]. Benefit is tied to the genetic diagnosis — the drug is not effective, and not indicated, for obesity without a qualifying variant. → Obesity Workup
Side effects
Common: injection-site reactions, skin hyperpigmentation / darkening of skin and moles (an on-target effect — MC1R activation affects pigmentation), nausea, and, distinctively, spontaneous penile erections in males and other sexual effects.
Less common / serious: depression and suicidal-ideation signals warranting mood monitoring; new or changing skin lesions warrant dermatologic evaluation (a full skin exam before and during treatment is advised).
Contraindications & cautions
- Absence of a qualifying genetic diagnosis — the drug is simply not indicated; genetic confirmation is a prerequisite.
- Pre-existing depression / suicidal ideation — caution and monitoring.
- Skin lesions of concern — dermatologic assessment before and during use (pigmentary effects can obscure or alter moles).
- Pregnancy — not recommended (see below).
Monitoring, pregnancy and surgery
- Monitoring: skin examination (pigmentation and moles) before and periodically during treatment; mood and mental-health screening; growth and development in children; hunger and weight response.
- Pregnancy/lactation: not recommended in pregnancy; weight loss is not a pregnancy goal. → Women's Health & Obesity
- Perioperative: no gastric-emptying concern like the GLP-1s; disclose all medications.
Long-term considerations, discontinuation and weight regain
For qualifying patients, setmelanotide addresses a lifelong genetic condition, so it is used as long-term therapy; as with other appetite-directed treatments, stopping is expected to be followed by return of hyperphagia and weight regain, because the underlying genetic defect persists. This makes durable, specialist-led treatment the norm. Setmelanotide also reframes the whole library: it shows that when the specific biology is known, treatment can be matched precisely — the direction the field is moving toward for the majority whose obesity is polygenic. → Genetics of Obesity · The Next Generation of Obesity Medicine
Unanswered questions
- Long-term (multi-decade) safety, especially skin/pigmentary and psychiatric outcomes.
- Whether additional genetic subtypes will qualify as diagnostics improve.
- The broader lesson for precision obesity medicine in common (polygenic) disease — still experimental.
Questions patients ask
What is setmelanotide used for?
It treats rare genetic obesity from specific leptin–melanocortin pathway defects — POMC/PCSK1 or LEPR deficiency and Bardet-Biedl syndrome — by directly activating the MC4R appetite receptor. Grade A 🟢 → Genetics of Obesity
Can I take it for regular (common) obesity?
No — it's only for confirmed qualifying genetic diagnoses, where the specific pathway is broken. In common obesity that pathway is intact, so no benefit is expected. Grade A 🟢
How do I know if I qualify?
Through genetic testing, usually after a picture of early-onset severe obesity with extreme hunger. Diagnosis is made in specialist settings before the drug is considered. Grade A 🟢 → Obesity Workup
Why does it darken the skin?
The MC4R receptor is related to MC1R, which controls pigmentation, so skin and mole darkening is an expected on-target effect. Skin should be examined before and during treatment. Grade A 🟢
Is this the same as Ozempic or Wegovy?
No — those are GLP-1 drugs for common obesity. Setmelanotide is a precision MC4R-pathway drug for specific rare genetic conditions only. Grade A 🟢 → Obesity Medication Library
Will hunger and weight return if it's stopped?
Yes — the genetic defect is lifelong, so stopping is expected to bring back the intense hunger and weight. It's used as long-term, specialist-monitored therapy. Grade A 🟢
KEEP READING
- Genetics of Obesity — the leptin–melanocortin pathway and monogenic obesity explained.
- Obesity Medication Library — how setmelanotide differs from every general obesity drug.
- The Next Generation of Obesity Medicine — precision therapy as the field's direction.
- Pediatric & Adolescent Obesity — early-onset severe obesity and when to test genes.
- How Obesity Should Be Evaluated — when genetic evaluation is appropriate.
Written by Darius A. Schneider, MD, PhD · Board-Certified Endocrinologist (ECNU) · Last updated: 2026-08-10 · References: Imcivree (setmelanotide) FDA prescribing information; pivotal POMC/PCSK1, LEPR and Bardet-Biedl syndrome trials. Educational only; setmelanotide is indicated only for confirmed qualifying genetic diagnoses and this is not individualized medical advice.
